Briefing
Circulating tumor DNA to guide changes in standard of care chemotherapy
Phase 2 trial in metastatic HER2-negative or triple-negative breast cancer whose title states that ctDNA is used to guide changes in chemotherapy. The registry primary outcome is progression-free survival. ClinicalTrials.gov lists the study as recruiting.
- Design: Phase 2 · Recruiting